Intellectual Property

BARD1 has established a strong intellectual property portfolio covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The IP portfolio comprises 5 patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan.

Patent Family
Title
Status
Expiry
Granted
 Pending
PCT/FR01/02731
Truncated BARD1 protein and its diagnostic and therapeutic uses
US, JP
2023
PCT/IB2011/053635
BARD1 isoforms in lung and colorectal cancer and use thereof
JP, CN
US (allowed), JP, CN (divisionals), EP, CA, IL, AU, BR, SG
2031
PCT/IB2011/054194
Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof
US, EP
2032
PCT/EP2014/073834
Lung Cancer Diagnosis
US, EP, CA, JP, IL, CN, AU, SG, KR
2034
EP14002398.7
Novel non-coding RNA, cancer target and compounds for cancer treatment
US
2035